Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? (RIPCORD 2)

A Randomised Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease.

A randomised controlled trial to compare two strategies for the investigation of coronary artery disease at the time of angiography. Patients will be randomised to conventional angiography or additional, routine pressure wire assessment - measuring fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow percutaneous coronary intervention (PCI) (experimental arm).

Studie Overzicht

Gedetailleerde beschrijving

The study will recruit patients undergoing angiography for the investigation of stable angina or for the assessment of a recent, but stabilised, non-ST elevation acute coronary syndrome event. Eligible patients who provide written informed consent will be randomised to conventional angiography or additional, routine pressure wire assessment - measuring fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow percutaneous coronary intervention (PCI) (experimental arm). The study pragmatic design allows investigators to conduct all diagnostic and therapeutic management in accordance with prevailing best practice patterns. Study outcome measures will examine resource utilisation, patient reported quality of life and clinical events at 1 year.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

1100

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Bristol, Verenigd Koninkrijk, BS2 8HW
        • Bristol Heart Institute - University Hospitals Bristol NHS Foundation Trust
    • Dorset
      • Bournemouth, Dorset, Verenigd Koninkrijk, BH7 7DW
        • Royal Bournemouth Hospital - The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
    • East Sussex
      • Brighton, East Sussex, Verenigd Koninkrijk, BN2 5BE
        • Brighton and Sussex University Hospitals NHS Trust
    • Hampshire
      • Portsmouth, Hampshire, Verenigd Koninkrijk, PO6 3LY
        • Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust
      • Southampton, Hampshire, Verenigd Koninkrijk, SO16 6YD
        • Southampton General Hospital - University Hospitals Southampton NHS Foundation Trust
    • Lancashire
      • Blackburn, Lancashire, Verenigd Koninkrijk, BB2 3HH
        • Royal Blackburn Teaching Hospital - East Lancashire Hospitals NHS Trust
    • Merseyside
      • Liverpool, Merseyside, Verenigd Koninkrijk, L14 3PE
        • Liverpool Heart and Chest Hospital NHS Foundation Trust
    • Northumberland
      • Newcastle upon Tyne, Northumberland, Verenigd Koninkrijk, NE7 7DN
        • Freeman Hospital - Newcastle Hospitals
    • Nottinghamshire
      • Mansfield, Nottinghamshire, Verenigd Koninkrijk, NG17 4JL
        • King's Mill Hospital - Sherwood Forest Hospitals NHS Foundation Trust
      • Nottingham, Nottinghamshire, Verenigd Koninkrijk, NG5 1PB
        • City Hospital - Nottingham University Hospitals NHS Trust
    • Scotland
      • Glasgow, Scotland, Verenigd Koninkrijk, G81 4DY
        • Golden Jubilee National Hospital
    • South Yorkshire
      • Sheffield, South Yorkshire, Verenigd Koninkrijk, S5 7AU
        • Northern General Hospital - Sheffield Teaching Hospitals
    • Staffordshire
      • Stoke-on-Trent, Staffordshire, Verenigd Koninkrijk, ST4 6QG
        • Royal Stoke University Hospital - University Hospitals of North Midlands
    • West Midlands
      • Birmingham, West Midlands, Verenigd Koninkrijk, B15 2TH
        • Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust
    • West Yorkshire
      • Wakefield, West Yorkshire, Verenigd Koninkrijk, WF1 4DG
        • Pinderfields Hospital - The Mid Yorkshire Hospitals NHS Trust
    • Yorkshire
      • Hull, Yorkshire, Verenigd Koninkrijk, HU16 5JQ
        • Castle Hill Hospital - Hull and East Yorkshire Hospitals NHS Trust
      • Leeds, Yorkshire, Verenigd Koninkrijk, LS1 3EX
        • Leeds General Infirmary - Leeds Teaching Hospitals NHS Trust

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

· Inclusion criteria

o Outline Initial Inclusion Criteria (before entry to cath lab):

Patient scheduled for coronary angiography for the:

  • Elective investigation of known or suspected coronary artery disease OR
  • Urgent investigation of a recent but stabilised, non-ST elevation acute coronary syndrome event

    o Outline Angiographic Inclusion Criterion (after angiography):

  • Presence of significant coronary disease defined as:

Any stenosis >30% reduction in luminal diameter, by visual estimate, in at least one vessel (main or branch) of sufficient calibre to permit the potential performance of PCI - approximately 2.25 mm diameter.

  • Key Exclusion Criteria

    • Screening phase exclusion criteria:

      • ≤ 18 years of age
      • Previous enrolment in this trial
      • Currently enrolled into another study unless co-enrolment approved by Chief Investigator (CI) and the clinical trials unit (CTU)
      • Inability to provide informed consent
      • Residence outside the United Kingdom (UK) or other issues limiting the ability to secure clinical follow-up data to one year
      • Non-cardiac pathology that may limit survival in the next year
      • Clear contraindication to potential future management with CABG or PCI (patients should be a potential candidate for medical therapy or revascularisation with either PCI or surgery)
      • Heart valve disease of sufficient import to consider valve replacement or other intervention as part of an index management strategy
      • Hypertrophic cardiomyopathy
      • Previous coronary artery surgery of any type
      • Known chronic renal impairment with a current estimated glomerular filtration rate (eGFR) of < 45
      • Anaemia with a current measured haemoglobin of < 100
      • Angiography performed in the context of an ST elevation myocardial infarction event
      • Any patient who at the time of planned angiography manifests haemodynamic instability, or recurrent sustained ventricular arrhythmia, or Mobitz type II or complete heart block
      • Any patient who at the time of planned angiography manifests unstable chest pain symptoms at rest or has required the continuing use of intravenous nitrates or regular opioid analgesia to control symptoms
      • Continuing use of intravenous glycoprotein 2b/3a (GP2b3a) agents before entry to the catheterisation laboratory
      • Known intolerance, hypersensitivity or contraindication to adenosine - including significant reversible airways disease
      • Additional investigations planned (or deemed likely to be required) for the assessment of myocardial ischaemia or viability. Examples of proposed tests that would constitute an exclusion criterion would include, but are not limited to, exercise tolerance testing, stress echocardiography, cardiac MRI viability or perfusion scanning or nuclear myocardial perfusion scanning.
      • Active bleeding at the time of planned index angiography
      • Pregnant women
    • Angiographic phase exclusion criteria:

      • Single vessel occlusive coronary disease (TIMI flow <3) as sole disease
      • Patient not suitable for the immediate performance of a pressure wire assessment of all major vessels for any reason, for example:

        • Patient discomfort
        • Change in the clinical condition or complication of angiography requiring termination of the procedure or immediate intervention
        • Significant use of radiographic contrast or X-Ray exposure during the initial angiography
        • Inadequate angiographic images or failure to intubate any of the coronary vessels
        • Aorto-ostial disease that would preclude accurate assessment of FFR
        • Insufficient laboratory time
        • Uncertain availability of key clinical and trial staff
        • PW use in coronaries declared unsafe (e.g. tight or long disease)
        • PW use in coronaries declared unsuitable (e.g. distal disease or complete cross-filling)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Diagnostisch
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Geen tussenkomst: Conventional angiography
Routine angiography will be performed according to local best practice
Experimenteel: Routine Measurement of FFR
Additional investigation with the measurement of FFR in all major vessels
FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow <3 will not be examined but will be 'awarded' an FFR value of 0.5
Andere namen:
  • Pressure wire assessment

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Primary Economic Outcome Measure
Tijdsspanne: One year
Resource utilisation as determined by hospital care costs at one year; All hospital admissions will be tracked using national hospital episode statistics; the cost of each episode will be derived from a cost model using standard UK tariffs. This analysis will compare the mean (or median) of the total hospital costs recorded for each patient over the 12 month follow-up period.
One year
Primary Quality of Life Outcome Measure
Tijdsspanne: One year
Patient reported quality of life at one year using the EQ-5D health questionnaire.
One year

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Sterfte door alle oorzaken
Tijdsspanne: Een jaar
Een jaar
Management strategy information
Tijdsspanne: Reported once: Single declaration at index procedure after randomisation
· Proportion of vessels deemed to demonstrate flow-limiting disease and targeted for revascularisation in the declared initial management strategy.
Reported once: Single declaration at index procedure after randomisation
Management strategy information
Tijdsspanne: Reported once: Single declaration at index procedure after randomisation
· Proportion of patients scheduled for management with medical therapy, percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) in the declared initial management strategy.
Reported once: Single declaration at index procedure after randomisation
Angina symptoms
Tijdsspanne: One year
• Angina symptoms as reported by the research team after the 12 month contact, described by Canadian Cardiovascular Society Grade.
One year
Angina symptoms
Tijdsspanne: One year
• Angina symptoms as reported by the patient with private completion of a screening form at 12 months, described by Canadian Cardiovascular Society Grade.
One year
Number of hospitalisation events
Tijdsspanne: One year
One year
Total hospital days
Tijdsspanne: One year
One year
Hospitalisation events
Tijdsspanne: One year
Hospitalisation events coded as cerebro-vascular accident (CVA).
One year
Hospitalisation events
Tijdsspanne: One year
Hospitalisation events coded as myocardial infarction.
One year
Hospitalisation events
Tijdsspanne: One year

Hospitalisation events coded as Coronary revascularisation. This analysis will involve a pre-specified subgroup analysis of:

  • Planned revascularisation - if declared as the index strategy.
  • All additional revascularisation events.
One year

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Nicholas Curzen, BM PhD FRCP, University Hospital Southampton NHS Foundation Trust
  • Hoofdonderzoeker: Rod H Stables, MA, DM, BM BCH, FRCP, Liverpool Heart and Chest Hospital NHS Foundation Trust

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 september 2016

Primaire voltooiing (Verwacht)

1 december 2019

Studie voltooiing (Verwacht)

1 maart 2020

Studieregistratiedata

Eerst ingediend

6 juli 2016

Eerst ingediend dat voldeed aan de QC-criteria

1 september 2016

Eerst geplaatst (Schatting)

8 september 2016

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 augustus 2019

Laatste update ingediend die voldeed aan QC-criteria

8 augustus 2019

Laatst geverifieerd

1 augustus 2019

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren